Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Raw Materials (2023 - 2025)

Verrica Pharmaceuticals has reported Raw Materials over the past 3 years, most recently at $1.0 million for Q2 2025.

  • Quarterly results put Raw Materials at $1.0 million for Q2 2025, down 12.27% from a year ago — trailing twelve months through Jun 2025 was $1.0 million (down 12.27% YoY), and the annual figure for FY2024 was $1.1 million, up 157.62%.
  • Raw Materials for Q2 2025 was $1.0 million at Verrica Pharmaceuticals, down from $1.0 million in the prior quarter.
  • Over the last five years, Raw Materials for VRCA hit a ceiling of $1.2 million in Q3 2024 and a floor of $116000.0 in Q3 2023.
  • Median Raw Materials over the past 3 years was $1.1 million (2024), compared with a mean of $897375.0.
  • Biggest five-year swings in Raw Materials: soared 941.38% in 2024 and later fell 12.27% in 2025.
  • Verrica Pharmaceuticals' Raw Materials stood at $420000.0 in 2023, then skyrocketed by 157.62% to $1.1 million in 2024, then fell by 6.84% to $1.0 million in 2025.
  • The last three reported values for Raw Materials were $1.0 million (Q2 2025), $1.0 million (Q1 2025), and $1.1 million (Q4 2024) per Business Quant data.